Stockscreener 앱 받기
1.2158
2.60%
0.0308
시간 외 거래:
1.22
0.0042
+0.35%
전일 마감가:
$1.185
열려 있는:
$1.18
하루 거래량:
3,180
Relative Volume:
0.06
시가총액:
$3.26M
수익:
-
순이익/손실:
$-4.69M
주가수익비율:
-0.5218
EPS:
-2.33
순현금흐름:
$-3.81M
1주 성능:
-4.27%
1개월 성능:
+0.48%
6개월 성능:
-34.28%
1년 성능:
-64.45%
1일 변동 폭
$1.17
$1.2158
1주일 범위
$1.17
$1.29
52주 변동 폭
$1.02
$3.74
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
명칭
Lixte Biotechnology Holdings Inc
전화
310 203 2902
주소
248 ROUTE 25A, EAST SETAUKET
LIXT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
1.2158 | 3.26M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lixte Biotechnology Holdings Inc 주식(LIXT)의 최신 뉴스
LIXTE Launches New Study to Determine if Certain - GlobeNewswire
Major Breakthrough? LIXTE's Cancer Prevention Drug Could Eliminate Pre-Cancerous Cells in Aging Adults - Stock Titan
LIXTE Biotechnology Updates Progress On LB-100 In Ovarian And Colorectal Cancer Trials - Nasdaq
LIXTE Biotechnology Provides Update On Progress with - GlobeNewswire
Major Breakthrough: LIXTE's Cancer Drug Shows Promise in New GSK, Roche Clinical Trials - Stock Titan
Lixte Biotechnology Holdings Inc. (LIXT) reports earnings - Quartz
Lixte Biotechnology revises sarcoma study agreement By Investing.com - Investing.com Australia
Lixte Biotechnology revises sarcoma study agreement - Investing.com
Lixte Biotech ends sales agreement, explores funding options By Investing.com - Investing.com South Africa
Lixte Biotechnology terminates sales agreement with Wallachbeth Capital -March 11, 2025 at 10:35 am EDT - Marketscreener.com
Lixte Biotech ends sales agreement, explores funding options - Investing.com
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form - GlobeNewswire
New Research Reveals Key Mechanism Behind LIXT's Cancer Drug LB-100 - StockTitan
LIXTE Adds Northwestern University’s Lurie Cancer Center as - GlobeNewswire
LIXTE Biotechnology Teams Up with Lurie Cancer Center to Initiate Clinical Trial of LB-100 and GSK’s Dostarlimab for Ovarian Clear Cell Cancer - Nasdaq
Can LIXTE's Cancer Drug Breakthrough Succeed Where Others Failed? Northwestern Joins Trial - StockTitan
Lixte Biotechnology faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India
Lixte Biotechnology Holdings, Inc. Announces Successful Closure of $1.05 Million Offering - Defense World
Lixte Biotechnology announces closing of $1.05M registered direct offering - Yahoo Finance
LIXTE Biotechnology Announces Closing of $1.05 Million - GlobeNewswire
Lixte Biotechnology Closes $1.1 Million Direct Offering -February 13, 2025 at 11:06 am EST - Marketscreener.com
LIXTE Biotechnology Holdings, Inc. Completes Registered Direct Offering and Private Placement Raising Approximately $1.05 Million - Nasdaq
LIXTE Secures Critical $1.05M Funding: Strategic Move Unlocks Next Growth Phase - StockTitan
LIXTE Biotechnology announces $1.05M registered direct offering; shares fall - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
LIXTE Biotech (LIXT) Secures Fresh Capital: Strategic $1.05M Direct Offering Includes Warrant Sweetener - StockTitan
Lixte Biotechnology Holdings Inc Inc. (LIXT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - GlobeNewswire
Lixte Biotechnology enters agreement for at-the-market stock sale - Investing.com
Lixte Biotechnology Holdings, Inc. Enters into At-the-Market Sales Agreement with WallachBeth Capital, LLC - Defense World
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World
Lixte Biotechnology Holdings, Inc. Vice President and COO Resigns - Defense World
Lixte Biotechnology announces executive departure By Investing.com - Investing.com Nigeria
Lixte Biotechnology announces executive departure - Investing.com
US Penny Stocks To Watch In December 2024 - Simply Wall St
LIXT (Lixte Biotechnology Holdings) 3-Year Sharpe Ratio : -0.39 (As of Dec. 05, 2024) - GuruFocus.com
LIXTE Biotechnology inks amendment to cancer drug study agreement - Investing.com
LIXTE Biotechnology inks amendment to cancer drug study agreement By Investing.com - Investing.com Nigeria
Lixte Biotechnology Holdings, Inc. Enters into Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam - Marketscreener.com
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
LIXTW (Lixte Biotechnology Holdings) Accounts Payable & Acc - GuruFocus.com
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
LIXT stock touches 52-week low at $1.53 amid market challenges - Investing.com Australia
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
LIXT stock touches 52-week low at $1.53 amid market challenges By Investing.com - Investing.com South Africa
Lixte Biotechnology Holdings Inc (LIXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):